Economic prognosis from vaccination against meningococcal infection inclusion into the National calendar of prophylactic vaccines in children of first age old
Open Access
- 2 August 2022
- journal article
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 2,p. 4-12
- https://doi.org/10.37489/2588-0519-2022-2-4-12
Abstract
Meningococcal infection (MI) is one of the severe illnesses by clinical manifestations and their consequences. Specific prophylaxis of severe MI forms is the most effective measure in the current conditions. It can lead to morbidity and disability reduction as well as and economic burden cut. Aim. Potential economic benefits of society finding in case of meningococcal polysaccharide conjugate vaccine to prevent MI caused by serogroups A, C, W, and Y into the National calendar of prophylactic vaccines (NCPV) for children 9- and 12-months age. Material and methods. The dynamic simulation mathematical model for epidemiological consequences of MI vaccines prophylaxis inclusion into NCPV was created. And economic calculations have been made based on this model also. Cost of vaccination based on prognosis of children amount in age before one year has been calculated, monetary equivalent of economic burden reduction in case of MI vaccines prophylaxis inclusion into NCPV was created. Results. Vaccination reduces mortality on 58–60 %, especially in children less than 5 years old. Correlation of the total epidemiological benefits expressed in years of prevented years of lost life with the projected cost of a statistical year of life gives the following results: starting from the 1st year of vaccination of children, society will receive almost 6.5 billion RUR monetary gain in metrics of life saved years. Monetary benefit on 10 years horizon could be as 70 billion RUR. Conclusion. Expenditures for meningococcal polysaccharide conjugate vaccine to prevent MI caused by serogroups A, C, W, and Y usage in case of inclusion into NCPV for children in 9- and 12-months (twice in the first year of life) are economic proved in frames of monetary equivalent of society gain in certain conditions.Keywords
This publication has 9 references indexed in Scilit:
- Cost-effectiveness of meningococcal vaccination of infants in the Russian FederationJournal Infectology, 2021
- Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in ChileHuman Vaccines & Immunotherapeutics, 2021
- Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap?Infectious Diseases Now, 2021
- Estimation of the Potential Benefits of Meningococcal Vaccination in Children at 9 and 12 Months of Age Using a Predictive Mathematical ModelEpidemiology and Vaccinal Prevention, 2020
- Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020MMWR. Recommendations and Reports, 2020
- The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccinationJournal of Infection, 2020
- Calendario de vacunaciones de la Asociación Española de Pediatría: recomendaciones 2020Anales de Pediatría, 2020
- Estimation of the real burden of invasive meningococcal disease in ArgentinaEpidemiology and Infection, 2019
- Neisseria meningitidis: using genomics to understand diversity, evolution and pathogenesisNature Reviews Microbiology, 2019